Ultrasensitive noninvasive disease monitoring platform
This project will leverage advances in nanotechnology to allow disease-specific enzymes to generate highly predictive ‘synthetic biomarkers’ that appear in the urine of patients for easy analysis. The approach dramatically broadens the number of diseases that could be detected and monitored by urinalysis and increases detection sensitivity and specificity. (Renewal from Fall 2013 grant round)
The technology from this project was spun out into a startup company, Glympse Bio.